Propanc Biopharma Inc
OTC:PPCB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Propanc Biopharma Inc
Total Receivables
Propanc Biopharma Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Propanc Biopharma Inc
OTC:PPCB
|
Total Receivables
$3k
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Receivables
$43.3m
|
CAGR 3-Years
104%
|
CAGR 5-Years
67%
|
CAGR 10-Years
19%
|
|
|
CSL Ltd
ASX:CSL
|
Total Receivables
$4.1B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Receivables
AU$32.3k
|
CAGR 3-Years
-71%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Receivables
AU$135.2m
|
CAGR 3-Years
51%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Receivables
AU$32.6m
|
CAGR 3-Years
55%
|
CAGR 5-Years
219%
|
CAGR 10-Years
74%
|
|
Propanc Biopharma Inc
Glance View
Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate PRP is a pharmaceutical composition consisting of two pancreatic proenzymes trypsinogen and chymotrypsinogen for treating cancer. PRP is an approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that targets and eradicates cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. PRP is a therapy based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas and could represent the body’s primary defense against cancer.
See Also
What is Propanc Biopharma Inc's Total Receivables?
Total Receivables
3k
USD
Based on the financial report for Jun 30, 2024, Propanc Biopharma Inc's Total Receivables amounts to 3k USD.
What is Propanc Biopharma Inc's Total Receivables growth rate?
Total Receivables CAGR 3Y
-11%
Over the last year, the Total Receivables growth was 3%. The average annual Total Receivables growth rates for Propanc Biopharma Inc have been -11% over the past three years .
